These studies examined a range of human responses to PPAR-α agonists, which included atherosclerosis, cardiovascular disease, serum biomarkers of fatty acid metabolism, acute toxicity, and, more limitedly, organ-specific chronic toxicity, including cancer. This evidence concerns the gene PPARA and cancer.